Cyclin-dependent kinase 4/6 inhibitors combined with stereotactic ablative radiotherapy in oligometastatic HR-positive/HER2-negative breast cancer patients
In advanced breast cancer patients treated with CDK4/6i, SABR provides a high local control and may provide additional benefit in an oligometastatic setting.
Authors
- Michał Jarząb (ORCID: https://orcid.org/0000-0002-2642-9724)
- Aleksandra Krzywon (ORCID: https://orcid.org/0000-0003-4796-5478)
- Dorota Gabryś (ORCID: https://orcid.org/0000-0001-9096-2788)
- Marcin Kubeczko (ORCID: https://orcid.org/0000-0003-1877-5691)
Institutions
- National Institute of Oncology (HU)
- The Maria Sklodowska-Curie National Research Institute of Oncology (PL)
Publication Details
- Journal
- British Journal of Radiology
- Published
- 2024-08-09
- DOI
- https://doi.org/10.1093/bjr/tqae138
- Citations
- 1
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.42